Toward Personalized Medicine in the Neuropsychiatric Field

International Review of Neurobiology

Volumn 101, Issue , 2011, Pages 329-349

  Wong, Erik H F ^a   Fox, Jayne C ^a   Ng, Mandy Y M ^a   Lee, Chi Ming ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Biomarkers; Disease classification; Genome; Molecular medicine; Neuropsychiatry; Stratification

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; GLYCOPROTEIN P; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

5HT1A RECEPTOR GENE; BOOK; DRUG RESEARCH; ENDOPHENOTYPE; ENVIRONMENTAL FACTOR; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; NEUROPSYCHIATRY; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL GENOMICS;

EID: 80055080725     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387718-5.00013-4     Document Type: Chapter

References (107)

1. Abbott A. Schizophrenia: the drug deadlock. Nature 2010, 468:158-159.
2. Agid Y., Buzsaki G., Diamond D.M., Frackowiak R., Giedd J., Girault J.A., Grace A., Lambert J.J., Manji H., Mayberg H., Popoli M., Prochiantz A., et al. How can drug discovery for psychiatric disorders be improved?. Nat. Rev. Drug Discov. 2007, 6:189-201.
3. Bergeron R., Imamura Y., Frangioni J.V., Greene R.W., Coyle J.T. Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. J. Neurochem. 2007, 100:346-357.
4. Bertilsson L., Dahl M.L., Dalen P., Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 2002, 53:111-122.
5. Binneman B., Feltner D., Kolluri S., Shi Y., Qiu R., Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 2008, 165:617-620.
6. Bloss C.S., Schork N.J., Topol E.J. Effect of direct-to-consumer genome wide profiling to assess disease risk. N. Engl. J. Med. 2011, 364:524-534.
7. Brown W.A. Treatment response in melancholia. Acta Psychiatr. Scand. 2007, 115:125-129.
8. Cannon T.D., Keller M.C. Endophenotypes in the genetic analyses of mental disorders. Annu. Rev. Clin. Psychol. 2006, 2:267-290.
9. Casciano D.A., Woodcock J. Empowering microarrays in the regulatory setting. Nat. Biotechnol. 2006, 24:1103.
10. Cirulli E.T., Goldstein D.B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 2010, 11:415-425.
11. Conn P.J., Roth B.L. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 2008, 33:2048-2060.
12. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 1996, 3:241-253.
13. Cryan J.F., Slattery D.A. Animal models of mood disorders: recent developments. Curr. Opin. Psychiatry 2007, 20:1-7.
14. Deverka P.A. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 2009, 12:149-157.
15. Devlin B., Roeder K. Genomic control for association studies. Biometrics 1999, 55:997-1004.
16. Dick D.M., Jones K., Saccone N., Hinrichs A., Wang J.C., Goate A., Bierut L., Almasy L., Schuckit M., Hesselbrock V., Tischfield J., Foroud T., et al. Endophenotypes successfully lead to gene identification: results from the collaborative study on the genetics of alcoholism. Behav. Genet. 2006, 36:112-126.
17. Domenici E., Wille D.R., Tozzi F., Prokopenko I., Miller S., McKeown A., Brittain C., Rujescu D., Giegling I., Turck C.W., Holsboer F., Bullmore E.T., et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010, 5:e9166.
18. Dorado P., Penas-Lledo E.M., Llerena A. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 2007, 8:1597-1608.
19. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808.
20. Durbin R.M., Abecasis G.R., Altshuler D.L., Auton A., Brooks L.D., Durbin R.M., Gibbs R.A., Hurles M.E., McVean G.A. A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073.
21. Egan M.F., Harper-Mozely L., Gottswald R., Snavely D. Effect of H3 inverse agonist MK-0249 on cognitive performance in patients with schizophrenia 2009.
22. Farde L. The advantage of using positron emission tomography in drug research. Trends Neurosci. 1996, 19:211-214.
23. Fava M., Rush A.J., Alpert J.E., Balasubramani G.K., Wisniewski S.R., Carmin C.N., Biggs M.M., Zisook S., Leuchter A., Howland R., Warden D., Trivedi M.H. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR D report. Am. J. Psychiatry 2008, 165:342-351.
24. Fisher P.M., Meltzer C.C., Ziolko S.K., Price J.C., Moses-Kolko E.L., Berga S.L., Hariri A.R. Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. Nat. Neurosci. 2006, 9:1362-1363.
25. Flordellis C.S. The emergence of a new paradigm of pharmacogenomics. Pharmacogenomics 2005, 6:515-526.
26. Franke R.M., Gardner E.R., Sparreboom A. Pharmacogenetics of drug transporters. Curr. Pharm. Des. 2010, 16:220-230.
27. Girirajan S., Eichler E.E. Phenotypic variability and genetic susceptibility to genomic disorders. Hum. Mol. Genet. 2010, 19:R176-R187.
28. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
29. Gonzalez I., Penas-Lledo E.M., Perez B., Dorado P., Alvarez M., LLerena A. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008, 9:833-840.
30. Goodsaid F., Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006, 7:773-782.
31. Goodsaid F., Frueh F.W. Implementing the U.S. FDA guidance on pharmacogenomic data submissions. Environ. Mol. Mutagen. 2007, 48:354-358.
32. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
33. Green E.D., Guyer M.S. Charting a course for genomic medicine from base pairs to bedside. Nature 2011, 470:204-213.
34. Grinker R.R. In retrospect: the five lives of the psychiatry manual. Nature 2010, 468:168-170.
35. Grozeva D., Kirov G., Ivanov D., Jones I.R., Jones L., Green E.K., St Clair D.M., Young A.H., Ferrier N., Farmer A.E., McGuffin P., Holmans P.A., et al. Rare copy number variants: a point of rarity in genetic risk for bipolar disorder and schizophrenia. Arch. Gen. Psychiatry 2010, 67:318-327.
36. Guilmatre A., Dubourg C., Mosca A.L., Legallic S., Goldenberg A., Drouin-Garraud V., Layet V., Rosier A., Briault S., Bonnet-Brilhault F., Laumonnier F., Odent S., et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch. Gen. Psychiatry 2009, 66:947-956.
37. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
38. Heekeren K., Daumann J., Neukirch A., Stock C., Kawohl W., Norra C., Waberski T.D., Gouzoulis-Mayfrank E. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl.) 2008, 199:77-88.
39. Herpfer I., Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005, 19:275-293.
40. Hong L.E., Hodgkinson C.A., Yang Y., Sampath H., Ross T.J., Buchholz B., Salmeron B.J., Srivastava V., Thaker G.K., Goldman D., Stein E.A. A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc. Natl. Acad. Sci. USA 2010, 107:13509-13514.
41. Hughes B. Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat. Rev. 2009, 8:523-524.
42. Insel T.R. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch. Gen. Psychiatry 2009, 66:128-133.
43. Insel T.R., Cuthbert B.N. Endophenotypes: bridging genomic complexity and disorder heterogeneity. Biol. Psychiatry 2009, 66:988-989.
44. International HapMap Consortium A haplotype map of the human genome. Nature 2005, 437:1299-1320.
45. International Human Genome Sequencing Consortium Finishing the euchromatic sequence of the human genome. Nature 2004, 431:931-945.
46. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752. International Schizophrenia Consortium.
47. Jain K.K. Applications of AmpliChip CYP450. Mol. Diagn. 2005, 9:119-127.
48. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 2007, 78:69-108.
49. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
50. Javitt D.C., Shelley A.M., Silipo G., Lieberman J.A. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch. Gen. Psychiatry 2000, 57:1131-1137.
51. Kantrowitz J.T., Javitt D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull. 2010, 83:108-121.
52. Kauwe J.S., Cruchaga C., Karch C.M., Sadler B., Lee M., Mayo K., Latu W., Su'a M., Fagan A.M., Holtzman D.M., Morris J.C. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS One 2011, 6(2):e15918. Alzheimer's Disease Neuroimaging Initiative.
53. Kendler K.S., Neale M.C. Endophenotype: a conceptual analysis. Mol. Psychiatry 2010, 15:789-797.
54. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 2004, 9:442-473.
55. Kirchheiner J., Seeringer A., Viviani R. Pharmacogenetics in psychiatry-a useful clinical tool or wishful thinking for the future?. Curr. Pharm. Des. 2010, 16:136-144.
56. Klein D.F. Causal thinking for objective psychiatric diagnostic criteria-a programmatic approach in therapeutic context. Causality and Psychopatholog 2011, Oxford University Press, London, p. 321.
57. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B.J., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
58. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., Sequeira A., Kushwaha N., Morris S.J., Basak A., Ou X.M., Albert P.R. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J. Neurosci. 2003, 23:8788-8799.
59. Li D., He L. G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. Genetics 2007, 175:917-922.
60. Licinio J. Translational Psychiatry: leading the transition from the cesspool of devastation to a place where the grass is really greener. Transl. Psychiatry 2011, 1.
61. Llerena A., Edman G., Cobaleda J., Benitez J., Schalling D., Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 1993, 87:23-28.
62. Losifescu D.V., Greenwald S., Devlin P., Mischoulon D., Denninger J.W., Alpert J.E., Fava M. Frontal EEG predictors of treatment outcome in major depressive disorder. Eur. Neuropsychopharmacol. 2009, 19:772-777.
63. Ma D., Salyakina D., Jaworski J.M., Konidari I., Whitehead P.L., Andersen A.N., Hoffman J.D., Slifer S.H., Hedges D.J., Cukier H.N., Griswold A.J., McCauley J.L., et al. A genome-wide association study of autism reveals a common novel risk locus at 5p14.1. Ann. Hum. Genet. 2009, 73:263-273.
64. Malenka R.C., Malinow R. Alzheimer's disease: recollection of lost memories. Nature 2011, 469:44-45.
65. McGrath P.J., Khan A.Y., Trivedi M.H., Stewart J.W., Morris D.W., Wisniewski S.R., Miyahara S., Nierenberg A.A., Fava M., Rush J.A. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR D report. J. Clin. Psychiatry 2008, 69:1847-1855.
66. McNally L., Bhagwagar Z., Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr. 2008, 13:501-510.
67. Meyer-Lindenberg A., Weinberger D.R. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat. Rev. Neurosci. 2006, 7:818-827.
68. Morrow D.A., Cannon C.P., Jesse R.L., Newby L.K., Ravkilde J., Storrow A.B., Wu A.H.B., Christenson R.H., Christenson R.H., Apple F.S., Cannon C.P., Francis G., et al. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin. Chem. 2007, 53:552-574.
69. Naatanen R., Kujala T., Winkler I. Auditory processing that leads to conscious perception: a unique window to central auditory processing opened by the mismatch negativity and related responses. Psychophysiology 2011, 48:4-22.
70. Nelson J.C. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress. Anxiety 2010, 27:12-18.
71. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13(10):1161-1169.
72. Ng P.C., Murray S.S., Levy S., Venter J.C. An agenda for personalized medicine. Nature 2009, 461:724-726.
73. Norton N., Williams H.J., Owen M.J. An update on the genetics of schizophrenia. Curr. Opin. Psychiatry 2006, 19:158-164.
74. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., Hamshere M., Carroll L., Georgieva L., Dwyer S., Holmans P., et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat. Genet. 2008, 40:1053-1055.
75. Oliver P.L., Davies K.E. Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk. Hum. Mol. Genet. 2009, 18:4576-4589.
76. Orr M.S., Goodsaid F., Amur S., Rudman A., Frueh F.W. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin. Pharmacol. Ther. 2007, 81:294-297.
77. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
78. Parker G., Wilhelm K., Mitchell P., Roy K., Hadzi-Pavlovic D. Subtyping depression: testing algorithms and identification of a tiered model. J. Nerv. Ment. Dis. 1999, 187:610-617.
79. Perry P.J. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J. Affect. Disord. 1996, 39:1-6.
80. Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 2006, 38:904-909.
81. Report of the National Advisory Mental Health Councils Workgroup From discovery to cure: accelerating the development of new and personalized interventions for mental illnesses 2010, http://www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/reports/fromdiscoverytocure.pdf.
82. Richardson-Jones J.W., Craige C.P., Guiard B.P., Stephen A., Metzger K.L., Kung H.F., Gardier A.M., Dranovsky A., David D.J., Beck S.G., Hen R., Leonardo E.D. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010, 65:40-52.
83. Riley B., Thiselton D., Maher B.S., Bigdeli T., Wormley B., McMichael G.O., Fanous A.H., Vladimirov V., O'Neill F.A., Walsh D., Kendler K.S. Replication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample. Mol. Psychiatry 2010, 15:29-37.
84. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995, 376:775-778.
85. Roses A.D. Genome-based pharmacogenetics and the pharmaceutical industry. Nat. Rev. Drug Discov. 2002, 1:541-549.
86. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
87. Rush A.J., Fava M., Wisniewski S.R., Lavori P.W., Trivedi M.H., Sackeim H.A., Thase M.E., Nierenberg A.A., Quitkin F.M., Kashner T.M., Kupfer D.J., Rosenbaum J.F., et al. Sequenced treatment alternatives to relieve depression (STAR D): rationale and design. Control. Clin. Trials 2004, 25:119-142.
88. Russell J.M., Koran L.M., Rush J., Hirschfeld R.M., Harrison W., Friedman E.S., Davis S., Keller M. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress. Anxiety 2001, 13:18-27.
89. Samuels B.A., Leonardo E.D., Gadient R., Williams A., Zhou J., David D.J., Gardier A.M., Wong E.H.F., Hen R. Modelling treatment resistant depression. Neuropharmacology 2011, 61:408-413.
90. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Rothermundt M., Bogerts B., Koethe D., Kranaster L., Ohrmann P., Suslow T., et al. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2011, 2011 Apr 12 (Epub ahead of print).
91. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
92. Shi L., Reid L.H., Jones W.D., Shippy R., Warrington J.A., Baker S.C., Collins P.J., de Longueville F., Kawasaki E.S., Lee K.Y., Luo Y., Sun Y.A., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 2006, 24:1151-1161.
93. Tan H.Y., Callicott J.H., Weinberger D.R. Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer?. Mol. Psychiatry 2008, 13:233-238.
94. Thase M.E. Maintenance therapy for bipolar disorder. J. Clin. Psychiatry 2008, 69:e32.
95. Uher R. The role of genetic variation in the causation of mental illness: an evolution-informed framework. Mol. Psychiatry 2009, 14:1072-1082.
96. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., Dose T., Ebinger M., Rosenhagen M., Kohli M., Kloiber S., Salyakina D., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008, 57:203-209.
97. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 2005, 76:1-23.
98. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 2000, 57:1139-1147.
99. Wain L.V., Tobin M.D. Copy number variation. Methods Mol. Biol. 2011, 713:167-183.
100. Wang K., Zhang H., Ma D., Bucan M., Glessner J.T., Abrahams B.S., Salyakina D., Imielinski M., Bradfield J.P., Sleiman P.M., Kim C.E., Hou C., et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 2009, 459:528-533.
101. Warden D., Rush A.J., Trivedi M.H., Fava M., Wisniewski S.R. The STAR D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007, 9:449-459.
102. Williams J.A., Andersson T., Andersson T.B., Blanchard R., Behm M.O., Cohen N., Edeki T., Franc M., Hillgren K.M., Johnson K.J., Katz D.A., Milton M.N., et al. PhRMA white paper on ADME pharmacogenomics. J. Clin. Pharmacol. 2008, 48:849-889.
103. Wong E.H.F., Nikam S.S., Shahid M. Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr. Opin. Investig. Drugs 2008, 9:28-36.
104. Wong E.H.F., Tarazi F.I., Shahid M. The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol. Ther. 2010, 126:173-185.
105. Wong E.H.F., Yocca F., Smith M.A., Lee C.M. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. Int. J. Neuropsychopharmacol. 2010, 13:1269-1284.
106. Woodcock J. Chutes and Ladders on the Critical Path: Comparative Effectiveness, Product Value, and the Use of Biomarkers in Drug Development. Clin. Pharm. & Ther. 2009, 86:12-14.
107. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.